H-2Kb TRP-2 Tetramer-SVYDFFVWL-PE

MBL Life Sciences

SKU: MBL-TS-5004-1C

Anti-mouse CD8 clone choice is critical when mouse MHC I tetramers, as some clones, including 53-6.7, lead to high background staining of all CD8+ T cells, rather than the antigen-specific ones. For best results, clone KT15, available from MBL International in FITC (K0227-4)is recommended. Additional information can be found in the datasheet that accompanies mouse class I tetramers, as well as the following reference containing a protocol for performing a cross titration series for optimization: Current Protocols in Immunology, MHC-Peptide tetramers to Visualize Antigen-Specific T Cells, Section 17.3.23-24, Supplement 59

Product Specifications

• Application: FC
• Reactivity: Mouse
• Conjugation: PE
• Peptide Sequence: SVYDFFVWL
• Class: Class I
• Sequence Location: 180-188
• MHC Allele: H-2K^b

Citations for H-2Kb TRP-2 Tetramer-SVYDFFVWL-PE – 4 Found

Mu, Li-Min; Liu, Lei; Liu, Rui; Du, Ya-Fei; Luo, Qian; Xu, Jia-Rui; Xie, Ying; Lu, Wan-Liang. Nanostructured SL9-CpG Lipovaccines Elicit Immune Response for the Treatment of Melanoma. International Journal Of Molecular Sciences. 2019;20(9) 

Kuwada, Eri; Kambara, Kaori; Tadaki, Toshimasa; Noguchi, Katsuo. Insoluble fraction of tumor cell homogenate is a useful material for eliciting cytotoxic T lymphocytes: a unique method for protein solubilization. Anticancer Research. 2011;31(3):881-91. 

Okano, Fumiyoshi; Merad, Miriam; Furumoto, Katsuyoshi; Engleman, Edgar G. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. Journal Of Immunology (Baltimore, Md. : 1950). 2005;174(5):2645-52. 

Takeshima, Tsuguhide; Chamoto, Kenji; Wakita, Daiko; Ohkuri, Takayuki; Togashi, Yuji; Shirato, Hiroki; Kitamura, Hidemitsu; Nishimura, Takashi. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Research. 2010;70(7):2697-706.